The ASCO annual meeting took place virtually beginning of June, where multiple companies presented their updated results of ongoing trials.
This led to share price changes and therefore to NBI increased beginning of June by 6% and remains now consistent.
Monthly market moves of selected competitors compared to NASDAQ Biotechnology Index (NBI)
|
Area |
Company |
Ticker |
Price range $ |
Δ Price |
MktCap $m |
ΔMktCap $m |
|
|
ADC |
ADC Therapeutics |
ADCT |
21.64 – 25.34 |
10 |
% |
1,868 |
168 |
|
Immunogen |
IMGN |
5.79 – 6.96 |
7 |
% |
1,318 |
90 |
|
|
Mersana Therapeutics |
MRSN |
13.28 – 15.00 |
-5 |
% |
945 |
-47 |
|
|
Seattle Genetics |
SGEN |
147.00 – 161.10 |
3 |
% |
28,652 |
704 |
|
|
IL 15/2 |
Alkermes |
ALKS |
23.07 – 25.15 |
6 |
% |
3,934 |
220 |
|
Nektar Therapeutics |
NKTR |
16.52 – 18.08 |
-5 |
% |
3,128 |
-168 |
|
|
Xencor |
XNCR |
34.33 – 39.06 |
-12 |
% |
2,008 |
-266 |
|
|
CAR-T |
Allogene Therapeutics |
ALLO |
23.49 – 26.10 |
3 |
% |
3,691 |
100 |
|
Autolus Therapeutics |
AUTL |
6.26 – 7.96 |
5 |
% |
468 |
23 |
|
|
Bellicum Pharma |
BLCM |
2.86 – 3.66 |
15 |
% |
28 |
4 |
|
|
Mustang Bio |
MBIO |
3.24 – 3.81 |
0 |
% |
290 |
-1 |
|
|
Other |
Arcus Biosciences |
RCUS |
22.75 – 29.04 |
12 |
% |
1,950 |
204 |
|
Immutep |
IMMP |
3.87 – 5.21 |
-26 |
% |
251 |
-87 |
|
|
Clovis Oncology |
CLVS |
5.13 – 6.54 |
13 |
% |
606 |
70 |
|
ADCT announced that updated interim results from the ongoing pivotal Phase 2 trial of camidanlumab tesirine in patients with relapsed or refractory Hodgkin lymphoma were presented at the 16th Annual International Conference on Malignant Lymphoma. ORR was 66.3% (67/101 patients) with a CRR of 27.7% and PRR of 38.6%. To date, nine patients (7.7%) were able to proceed to HSCT following Cami treatment.
The short interest of Immunogen increased in June by 11% to 23,065,947 on June 15, compared to 20,854,878 on May 15.
Mersana’s Anna Protopapas, President and CEO, presented at the Jefferies Virtual Healthcare Conference on June 2, 2021.
Seagen announced that improvements in OS and PFS were maintained with long-term follow up from the pivotal HER2CLIMB trial evaluating the addition of Tukysa (tucatinib) to trastuzumab and capecitabine in patients with HER2-positive metastatic BRCA with and without brain metastases. The OS benefit seen with Tukysa at the time of the primary analysis was maintained after an additional 15.6 months of follow-up, demonstrating a 5.5-month improvement in median OS (24.7 months for Tukysa regimen vs. 19.2 months for capecitabine and trastuzumab alone). This benefit continued to be generally consistent across pre-specified patient subgroups.
Alkermes announced new data from its ARTISTRY clinical development program for nemvaleukin alfa, Alkermes' novel, investigational engineered IL-2 variant immunotherapy. Durable and deepening responses have been observed with IV nemvaleukin, as monotherapy or in combination with pembrolizumab, in platinum-resistant OVCA and mucosal melanoma.
Nektar announced its senior management participated in a virtual fireside chat at the upcoming Goldman Sachs 42nd Global Healthcare Conference on June 8, 2021.
Xencor’s Bassil Dahiyat, president and CEO, presented a corporate overview at the Jefferies Healthcare Conference on June 3, 2021.
Allogene presented data from multiple studies across lead anti-CD19 AlloCAR T therapy programs in two poster presentations at ASCO. ALLO-501 demonstrated ORR of 75% and CR Rate of 50% across histologies in CAR-T naïve patients on par with autologous CAR-T therapies. ALLO-501A demonstrated comparable safety and efficacy results.
Autolus Therapeutics
Autolus announced that it has received innovative licensing and access pathway (ILAP) designation from the UK Medicines and Healthcare products Regulatory Agency for AUTO1 (obe-cel), the CAR-T cell therapy being investigated in the ongoing FELIX Phase 1b/2 study in relapsed / refractory (r/r) adult B-cell ALL. The company recently announced that Obe-cel achieved 100% CRR in a cohort of indolent B Cell NHL patients.
Bellicum has entered into a license agreement with the University of North Carolina Lineberger Comprehensive Cancer Cente and Massachusetts General Hospital covering certain intellectual property and technology rights regarding the company’s CaspaCIDe (inducible caspase-9, or iC9) safety switch and related technologies, and the use of rimiducid.
Mustang announced updated interim Phase 1/2 data for its MB-106 CD20-targeted CAR-T in patients with relapsed or refractory B-cell NHL and CLL. The CAR-T therapy achieved 93% ORR and 67% CR in mid-stage leukemia trial. The data were presented at European Hematology Association 2021 congress.
Shares of Arcus gained after the company said its experimental lung-cancer PD-L1 treatment domvanalimab demonstrated clinical activity in an open-label, Phase 2 clinical study. Arcus did not release specific data but said the trial will continue. Gilead recently increased its stake in Arcus to 19% from 13% and has the exclusive option to co-develop the drug.
Immutep has signed an agreement to commence a new Phase 1 trial, called INSIGHT-003, to evaluate the combination of its eftilagimod alpha in conjunction with an existing approved standard of care therapy consisting of a chemotherapy agent and an anti-PD-1 therapy. Separately, Immutep announced it has received commitments for a A$60 million two-tranche placement of new shares.
The short interest of Clovis decreased in June by 9% to 28,646,533 on June 15, compared to 31,435,972 on May 15.
